Advertisement

Cell Biology and Toxicology

, Volume 35, Issue 1, pp 59–66 | Cite as

Characterization of circulating tumor cells in breast cancer patients by spiral microfluidics

  • Jianhua Yin
  • Zhifeng Wang
  • Guibo Li
  • Feng Lin
  • Kang Shao
  • Boyang Cao
  • Yong HouEmail author
Original Article

Abstract

Circulating tumor cells (CTCs) have important application prospects in the early diagnosis, treatment evaluation, and prognostic prediction of tumors. In this study, we enrolled a total of 65 patients with different stages and molecular subtypes of breast cancer and isolated and enriched for CTCs from peripheral blood using the ClearCell FX1 platform, which is based on a label-free spiral microfluidic method. The ClearCell platform can successfully isolate CTCs from peripheral blood with different detection rates in breast cancer patients. We also compared the difference between the ClearCell and CellSearch platforms for isolating CTCs. To further determine the genetic information of CTCs, we performed single-cell whole-exome sequencing (WES) in three CTCs isolated from one patient. The sequencing results indicated the presence of a few hundreds of single-nucleotide variants (SNVs) in each CTC, with only 16 SNVs being shared by all three CTCs. These shared SNVs may have a crucial impact on the development of breast cancer. Here, we report, for the first time, the complete process and results of performing single-cell WES on CTCs isolated by the ClearCell FX1 platform.

Keywords

Circulating tumor cells Breast cancer ClearCell CellSearch WES 

Notes

Acknowledgments

This study was supported by the Shenzhen Municipal Government of China (JSGG20140702161347218)

Supplementary material

10565_2018_9454_MOESM1_ESM.docx (300 kb)
ESM 1 (DOCX 299 kb)

References

  1. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110–8.CrossRefGoogle Scholar
  2. Arya SK, Lim B, Rahman AR. Enrichment, detection and clinical significance of circulating tumor cells. Lab Chip. 2013;13:1995–2027.CrossRefGoogle Scholar
  3. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10:472–84.CrossRefGoogle Scholar
  4. De Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–9.CrossRefGoogle Scholar
  5. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218–24.CrossRefGoogle Scholar
  6. Hou HW, Warkiani ME, Khoo BL, Li ZR, Soo RA, Tan DS, et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 2013;3:1259.CrossRefPubMedCentralGoogle Scholar
  7. Kandoth C, Mclellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9.CrossRefPubMedCentralGoogle Scholar
  8. Khoo BL, Warkiani ME, Tan DS, Bhagat AA, Irwin D, Lau DP, et al. Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. PLoS One. 2014;9:e99409.CrossRefPubMedCentralGoogle Scholar
  9. Lin E, Cao T, Nagrath S, King MR. Circulating tumor cells: diagnostic and therapeutic applications. Annu Rev Biomed Eng. 2018;20:329–52.CrossRefGoogle Scholar
  10. Maheswaran S, Haber DA. Ex vivo culture of CTCs: an emerging resource to guide cancer therapy. Cancer Res. 2015;75:2411–5.CrossRefPubMedCentralGoogle Scholar
  11. Rhim AD, Thege FI, Santana SM, Lannin TB, Saha TN, Tsai S, et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology. 2014;146:647–51.CrossRefGoogle Scholar
  12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.CrossRefGoogle Scholar
  13. Tan CL, Lim TH, Lim T, Tan DS, Chua YW, Ang MK, et al. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. Oncotarget. 2016;7:23251–62.PubMedCentralGoogle Scholar
  14. Teo J, Mirenska A, Tan M, Lee Y, Oh J, Hong LZ, et al. A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry. Future Sci OA. 2017;3:FSO244.CrossRefPubMedCentralGoogle Scholar
  15. Thiele JA, Bethel K, Kralickova M, Kuhn P. Circulating tumor cells: fluid surrogates of solid tumors. Annu Rev Pathol. 2017;12:419–47.CrossRefGoogle Scholar
  16. Warkiani ME, Khoo BL, Tan DS, Bhagat AA, Lim WT, Yap YS, et al. An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells. Analyst. 2014;139:3245–55.CrossRefGoogle Scholar
  17. Warkiani ME, Khoo BL, Wu L, Tay AK, Bhagat AA, Han J, et al. Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics. Nat Protoc. 2016;11:134–48.CrossRefGoogle Scholar
  18. Witzel I, Muller V. Targeted therapies in breast cancer: new approaches and old challenges. Breast Care (Basel). 2015;10:157–8.CrossRefGoogle Scholar
  19. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345:216–20.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.BGI-ShenzhenShenzhenChina
  2. 2.China National GeneBank, BGI-ShenzhenShenzhenChina

Personalised recommendations